Overview

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
Phase:
Phase 4
Details
Lead Sponsor:
Kenneth H. Mayer, MD
Collaborators:
Abbott
Bristol-Myers Squibb
Gilead Sciences
Treatments:
Atazanavir Sulfate
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Ritonavir
Tenofovir